Quantum Genomics (QGC), Inserm, CNRS, and the University Paris Descartes are collaborating to develop drugs for hypertension and related cardiovascular diseases.
The first compound, QGC001, to be pursued will be a candidate from discoveries by teams led by Catherine Llorens-Cortes, director of Inserm Unit 691, and Bernard P. Roques at Inserm Unit 640, based in the University of Paris Descartes. QGC expects to start a clinical trial in 2008.
Under the terms of the contract, QGC acquires rights to exploit three patents and associated know-how. Inserm and CNRS will work on the physiopathology, chemistry, and understanding of the compound's mechanism of action, whereas QGC will handle preclinical and clinical development and regulatory aspects.